Government powers have reported that they are evaluating the likelihood of slackening the classification of cannabis, and on the off chance that this happens, it could have an expansive effect on how the substance is utilized as a part of medical settings, specialists said. Pot is at the moment named a Schedule I drug, which means it is listed with heroin and LSD as among the “most dangerous drugs” and has “no currently accepted medical use and a high potential for abuse.”
The Drug Enforcement Agency declared a week ago that it is exploring the likelihood of renaming it as a Schedule II drug, which would place it in the same classification as Ritalin, Adderal, and oxycodone. Therapeutic specialists are respecting the review, saying it could ease limitations for analysis, with the goal that they can better comprehend which mixes in cannabis could be utilized to help patients. The American Medical Association told ABC News that the gathering backed the review “to help facilitate scientific research and the development of cannabinoid-based medicines.”
“The Drug Enforcement Administration should work with other federal regulatory agencies to develop a special schedule for marijuana to facilitate a study of its potential medical utility in prescription drug products,” said AMA officials to ABC News. “Current standards for approval of prescription drug products require rigorous scientific study. While studies related to a limited number of medical conditions have shown promise for new cannabinoid-based prescription products, the scope of rigorous research needs to be expanded to a broader range of medical conditions for such products.”
According to Dr. Kevin Hill, assistant professor of psychiatry at McLean Hospital and Harvard Medical School, there are “hoops you have to run through for this research. If you use marijuana itself, you have to get special licensing from the DEA. It involves a background visit and … they don’t give it out very easily.”
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
